CHRS
Companies
NASDAQ
Coherus Biosciences Inc.
Health Care
$0.77
-$0.61 (-44.38%)
Price Chart
Overview
About CHRS
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
Market Cap
$193.9M
Volume
1.5M
Avg. Volume
1.4M
P/E Ratio
-3.0225925
Dividend Yield
0.00%
Employees
341.0
Company Information
Risk & Correlation Analysis
Market Correlation
2.28
High Correlation
Volatility
High (0.99)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, CHRS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$193.9M
Volume1.5M
P/E Ratio-3.02
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 13, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025